Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ONT-093 (Ontogen).

Prakash Mistry1, Adrian Folkes

  • 1Xenova Ltd, 957 Buckingham Avenue, Slough, Berkshire, SL1 4NL, UK. prakash_mistry@xenova.co.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|December 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

Journal of medicinal chemistry·2022
Same author

Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.

Bioorganic & medicinal chemistry letters·2010
Same author

Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.

Journal of medicinal chemistry·2010
Same author

H4 histamine receptors mediate cell cycle arrest in growth factor-induced murine and human hematopoietic progenitor cells.

PloS one·2009
Same author

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.

Molecular cancer therapeutics·2009
Same author

Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases.

Cancer chemotherapy and pharmacology·2008

ONT-093 is a novel P-glycoprotein pump inhibitor being developed to combat multidrug resistance in cancer chemotherapy. This compound may also improve drug bioavailability and central nervous system penetration for P-glycoprotein substrate drugs.

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Development

Background:

  • Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy, limiting treatment efficacy.
  • P-glycoprotein (P-gp) is a key efflux pump responsible for MDR by extruding chemotherapeutic agents from cancer cells.
  • P-gp also affects the oral bioavailability and central nervous system (CNS) penetration of various drugs.

Purpose of the Study:

  • To evaluate ONT-093, a P-glycoprotein pump inhibitor, for its potential to reverse multidrug resistance in cancer patients.
  • To assess the capacity of ONT-093 to enhance the oral bioavailability of P-glycoprotein substrate drugs.
  • To investigate the potential of ONT-093 to improve CNS penetration of P-glycoprotein substrate drugs.

Main Methods:

  • Preclinical studies involving P-glycoprotein inhibition assays.

Related Experiment Videos

  • Pharmacokinetic studies to evaluate oral bioavailability.
  • In vivo models to assess CNS penetration and reversal of multidrug resistance.

    • Main Results:

    • ONT-093 demonstrated potent inhibition of P-glycoprotein activity.
    • Preliminary data suggests potential for enhanced oral bioavailability of P-gp substrate drugs.
    • Evidence indicates improved CNS penetration of P-gp substrate drugs in relevant models.

    Conclusions:

    • ONT-093 shows promise as a P-glycoprotein inhibitor for overcoming cancer multidrug resistance.
    • The compound may offer therapeutic benefits by improving drug delivery and efficacy.
    • Further clinical evaluation is warranted to confirm these findings in patients.